123706-69-4

Upstream product

• 2615-15-8 pentaethylene glycol 
• 40615-36-9 4,4'-dimethoxytrityl chloride 

Downstream Products

• 1443045-18-8 O-(4,4'dimethoxytrityl)hexaethyleneglycol-H-phosphonate 
• 125607-09-2 1-O-DMT-6-β-cyanoethyl-N,N-diisopropylphosphoramidite-hexaethylene glycol 

Relevant academic research and scientific papers

A fibre-optic biosensor for detection of microbial contamination

A fibre-optic biosensor is described for detection of genomic target sequences from Escherichia coli. A small portion of the LacZ DNA sequence is the basis for selection of DNA probe molecules that are produced by automated nucleic acid synthesis on the s

NUCLEIC ACID OF FORMULA (I): GlXmGn, OR (II): ClXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT

The present invention relates to a nucleic acid of the general formula (I): GlXmGn, or (II): ClXmCn, which may be modified by a lipid. The nucleic acid of the invention acts as an immune-stimulating agent inducing the innate immune response. The invention relates further to a pharmaceutical composition (in a first embodiment), each containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). In another embodiment, the inventive nucleic acid is combined with at least one pharmaceutically active component, a pharmaceutically acceptable carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). Accordingly, the present invention is directed to a vaccine, which corresponds to a pharmaceutical composition of the invention (second embodiment), wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention relates likewise to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune diseases, allergies or cancer diseases.

Oligo(2′-O-methylribonucleotides) and their derivatives: IV. Conjugates of oligo(2′-O-methylribonucleotides) with minor groove binders and intercalators: Synthesis, properties, and application

Triplex forming 3′-protected pyrimidine oligo(2′-O- methylribonucleotides) containing minor groove binders (MGB) and triplex specific intercalator, benzoindoloquinoline (BIQ), at the 5′-terminus were synthesized. The resulting conjugates formed stable complexes with a target dsDNA due to the simultaneous binding to the minor and major grooves and BIQ intercalation. The dissociation constants and the thermal stability were evaluated for the conjugate complexes with the model dsDNA corresponding to the polypurine tract (PPT) of the nef and pol genes from the HIV proviral genome. The conjugation of oligo(2′-O-methylribonucleotides) with MGB and BIQ was shown to increase the stability of the triple complexes with dsDNA at pH 7.2 and 37 C. Moreover, the intercalator accelerates the process of the complex formation. The dosedependent arrest of the in vitro transcription was demonstrated when a 780-bp DNA fragment containing the polypurine tract was transcribed under the control of T7 promoter in the presence of different concentrations of conjugates of oligo(2′-O-methylribonucleotides) containing MGB and BIQ.

Synthesis of guanosine 5′-conjugates and their use as initiator molecules for transcription priming

We have synthesised two guanosine derivatives that are linked to biotinylated adenosine moieties by using two different strategies, one that includes synthetic steps on the solid phase and another one that is performed entirely in solution. The synthesised derivatives were shown to function as initiator molecules in transcription priming experiments. The incorporation efficiency was determined to be approximately 2%. Even though this value is rather low, the use of either molecule in selection experiments seems reasonable. Basically, RNA libraries with sequence complexities of 10 15 to 1016 can be generated. Labelling of such a library with our initiator molecule would still produce 1013 to 10 14 labelled/functionalised sequences, and thus sufficient sequence space for selection. The Royal Society of Chemistry.

ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID

The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally a pharmaceutically acceptable carrier and/or further auxiliary substances and additives and/or further adjuvants. The present invention relates likewise to the use of the pharmaceutical composition according to the invention and of the vaccine according to the invention for the treatment of infectious diseases or cancer diseases. Likewise, the present invention includes the use of the immune-stimulating adjuvant according to the invention in the preparation of a pharmaceutical composition for the treatment of cancer diseases or infectious diseases.

A SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELL NUCLEI

A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Nove1 conjugates of biologically active moities and such oligomeric compounds, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically active substances to a desired target are further disclosed. Processes of preparing the conjugates and the oligomeric compounds and novel intermediates designed for and used in these processes are also disclosed.

ENCODED REACTION CASSETTE

A reaction cassette has been designed for the highly sensitive detection of the making and breaking of chemical bonds. The system may be employed as a companion device to be used in the search for antibody and other novel catalysts. The cassette also has important clinical applications in the design of diagnostic reagents. In its fully encoded format this methodology is capable of both detecting and decoding chemical events.

Binding of aminoglycoside antibiotics with modified A-site 16S rRNA construct containing non-nucleotide linkers

The design and synthesis of synthetically modified cyclic A-site 16S rRNA construct is reported. The binding characteristics of several members of the aminoglycoside antibiotics with this novel class of synthetically modified A-site 16S rRNA constructs we

Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes

This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.

Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes

This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.